Nektar Therapeutics edges lower after $100 mln stock sale

Shares of Nektar Therapeutics NKTR.O down 0.4% premarket to $25.74 after follow-on prices

San Francisco-based firm announces ~4.3 mln shares at $23.50 for $100 mln gross proceeds

Offering price represents 9.1% discount to stock's last close

Co intends to use net offering proceeds for R&D, clinical development and manufacturing costs to support advancement of its drug candidates, along with other general purposes

Jefferies and Piper Sandler are jt bookrunners for offering, joined by BTIG

Last Tues, NKTR shares soared 156% to close at $24.45 after co's eczema drug met main goal in mid-stage study

Shares have gained 171% over the past week, putting them up 85% YTD through Mon close

With ~12.4 mln shares outstanding, co has about $320 mln market cap

Earlier this month, co effected 1-for-15 reverse stock split